Understanding how to control mast cell activation to improve allergy treatments
Official title: Modulation and exploitation of Siglec-6 function to broadly impede mast cell activation
Funded at Northwestern University at Chicago · NIH-11051825 · Data updated 2026-11-12
This study is looking at how a special protein called Siglec-6 can help keep mast cells, which play a big role in allergic reactions, from getting too active, with the goal of finding better treatments for allergies like anaphylaxis and chronic hives that go beyond just easing symptoms.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project start | March 7, 2024 |
| Project end | January 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $441,537 |
| NIH project number | 5R01AI158697-02 |
| Project ID | NIH-11051825 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals with mast cell-driven allergic conditions such as anaphylaxis or chronic spontaneous urticaria.
✕Less likely to help
Patients with non-allergic conditions or those whose symptoms are not driven by mast cell activation may not benefit from this research.
What this research studies
This research investigates the role of Siglec-6, a receptor found on mast cells, in controlling their activation. By exploring how Siglec-6 can inhibit mast cell responses, the research aims to develop new therapeutic strategies that go beyond just alleviating symptoms of allergic reactions. The approach involves studying the signaling pathways activated by Siglec-6 and how they can be leveraged to create more effective treatments for conditions like anaphylaxis and chronic urticaria. Patients may benefit from improved therapies that target the underlying mechanisms of their allergic conditions.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients suffering from severe allergic reactions and related conditions.
How similar studies have gone: Previous research has shown promise in targeting similar receptors for controlling mast cell activation, indicating potential for success in this approach.
Where this research is happening
-
Northwestern University at Chicago
Chicago, United States Active
Researchers
- Principal investigator: O'sullivan, Jeremy a — Northwestern University at Chicago
- Study coordinator: O'sullivan, Jeremy a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.